您当前的位置:

信号通路

-收起全部分类

P2Y Receptor

P2Y Receptor相关产品(10)
货号 产品名 中文名称 产品描述
SJ-MX3739 BPTU BPTU (BMS-646786) is an allosteric P2Y1 antagonist. Prevents inhibition of spontaneous contraction of rat and mouse colon induced by electrical field stimulation, nicotine and P2Y agonists. Acts as n antithrombotic agent and reduces platelet aggregation.
SJ-MX0852 Cangrelor Tetrasodium 坎格雷洛四钠盐 Cangrelor tetrasodium 是一种三磷酸腺苷类似物,是一种可逆的、选择性的血小板 P2Y12 拮抗剂,具有迅速有效的抗血小板作用。Cangrelor tetrasodium 直接阻断腺苷二磷酸 (ADP) 诱导的血小板活化和聚集。Cangrelor tetrasodium 也是一种非特异性的 GPR17 拮抗剂。
SJ-MX2143 Ticagrelor 替卡格雷 Ticagrelor (AZD6140) 是可逆的,具有口服活性的 P2Y12 受体拮抗剂,可用来研究血小板聚集。
SJ-MX1834 MRS 2578 MRS 2578 是一种选择性强的 P2Y6 受体拮抗剂,IC50 为 37 nM (人) 和 98 nM (大鼠)。MRS 2578在 P2Y1、P2Y2、P2Y4 和 P2Y11 受体上活性不明显。
SJ-MX4369 N6-(4-Hydroxybenzyl) adenosine N6-羟苄腺苷 N6-(4-Hydroxybenzyl) adenosine抑制由胶原诱导的血小板聚集, IC50范围为6.77-141 μM。
SJ-MX4720 PIT PIT (2,2'-Pyridylisatogen tosylate) 是 P2Y1 受体 的选择性和非竞争性拮抗剂,对人 P2Y1 受体的 IC50 值为 0.14 μM。PIT 在不影响核苷酸结合的情况下拮抗 P2Y1 受体信号。PIT 是一些平滑肌中代谢性嘌呤受体 (P2Y 家族) 对 ATP 反应的不可逆拮抗剂。
SJ-MX3948 Uridine-5'-diphosphate disodium salt 尿苷-5'-二磷酸二钠盐 Uridine-5'-diphosphate disodium salt 是一种有效的选择性 P2Y6 受体激动剂 (EC50=300 nM; 对人 P2Y6 受体 pEC50=6.52)。Uridine-5'-diphosphate disodium salt 是一种内源性代谢产物 (endogenous metabolite),催化多种底物的葡糖醛酸糖化反应,可用于核酸生物合成 (RNA biosynthesis)。
SJ-MX2713 Prasugrel hydrochloride 盐酸普拉格雷 Prasugrel hydrochloride (formerly also known as CS-747, PCR 4099 and LY640315), a piperazine derivative, is a novel and potent thienopyridine ADP receptor (P2Y12) antagonist used for the reduction of thrombotic cardiovascular events. Prasugrel was also approved the use of prasugrel for the reduction of thrombotic cardiovascular events in patients with acute coronary syndrome who are to be managed with PCI.
SJ-MX3277 Prasugrel 普拉格雷 Prasugrel is novel thienopyridine antiplatelet prodrug that is metabolized to the thiol-containing active metabolite R-138727,which binds to and irreversibly inhibits the platelet P2Y12ADP receptor. Prasugrel is metabolized by the liver- and intestinal-dominant carboxylesterases CE1 and CE2 to give a mixture of four enantiomers that inhibit platelet aggregation.
SJ-MX2965 Clopidogrel hydrogen sulfate 硫酸氢氯吡格雷 Clopidogrel sulfate (Plavix; Zyllt; Osvix; Plavitor, SR-25990C), the sulfate salt of Clopidogrel, is an orally bioavailable, thienopyridine class of antiplatelet agent acting as an irreversible inhibitor of ADP receptor (P2Y12). Clopidogrel is a prodrug that has to be activated by CYP2C19. It is approved as an antiplatelet and anticoagulant medication used to reduce the risk of heart disease and stroke in those at high risk. Clopidogrel works by irreversibly inhibiting a receptor called P2Y12, an adenosine diphosphate (ADP) chemoreceptor on platelet cell membranes. Clopidogrel acts by inhibiting the ADP receptor on platelet cell membranes.